<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0501221566
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RESOVA 20MG FILM COATED TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        115.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Resova belongs to a group of medicines called statins. &nbsp;</p><p><strong>You have been prescribed Resova because: </strong></p><ul><li>You have a high cholesterol level. This means you are at risk from a heart attack or stroke. Resova is used in adults, adolescents and children 6 years or older to treat high cholesterol.&nbsp;</li><li>You have been advised to take a statin, because changing your diet and doing more exercise were not enough to correct your cholesterol levels. You should continue with your cholesterol-lowering diet and exercise while you are taking Resova.</li></ul><p>Or&nbsp;</p><ul><li>You have other factors that increase your risk of having a heart attack, stroke or related health problems.</li></ul><p>Heart attack, stroke and other problems can be caused by a disease called atherosclerosis. Atherosclerosis is due to build-up of fatty deposits in your arteries.</p><p><strong>Why it is important to keep taking Resova</strong><br />Resova is used to correct the levels of fatty substances in the blood called lipids, the most common of which is cholesterol.&nbsp;</p><p>There are different types of cholesterol found in the blood &ndash; &lsquo;bad&rsquo; cholesterol (LDL-C) and &lsquo;good&rsquo; cholesterol (HDL-C). &nbsp;&nbsp;</p><ul><li>Resova can reduce the &lsquo;bad&rsquo; cholesterol and increase the &lsquo;good&rsquo; cholesterol. &nbsp;</li><li>It works by helping to block your body&rsquo;s production of &lsquo;bad&rsquo; cholesterol. It also improves your body&rsquo;s ability to remove it from your blood.</li></ul><p>For most people, high cholesterol does not affect the way they feel because it does not produce any symptoms. However, if it is left untreated, fatty deposits can build up in the walls of your blood vessels causing them to narrow.</p><p>Sometimes, these narrowed blood vessels can get blocked which can cut off the blood supply to the heart or brain leading to a heart attack or a stroke. By lowering your cholesterol levels, you can reduce your risk of having a heart attack, a stroke or related health problems.</p><p>You need to keep taking Resova, even if it has got your cholesterol to the right level, because it prevents your cholesterol levels from creeping up again and causing build-up of fatty deposits. However, you should stop if your doctor tells you to do so, or you have become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Resova</strong><strong> </strong></p><ul><li>If you have ever had an allergic reaction to Resova, or to any of its ingredients.&nbsp;</li><li>If you are pregnant or breast-feeding. If you become pregnant while taking Resova stop taking it immediately and tell your doctor. Women should avoid becoming pregnant while taking Resova by using suitable contraception.</li><li>If you have liver disease.&nbsp;</li><li>If you have severe kidney problems.&nbsp;</li><li>If you have repeated or unexplained muscle aches or pains.&nbsp;</li><li>If you take a drug combination of sofosbuvir/velpatasvir/voxilaprevir (used for viral infection of the liver called hepatitis C).&nbsp;</li><li>If you take a drug called ciclosporin (used, for example, after organ transplants).</li></ul><p>If any of the above applies to you (or you are in doubt), please go back and see your doctor.</p><p>In addition, do not take rosuvastatin 40 mg (the highest dose):</p><ul><li>If you have moderate kidney problems (if in doubt, please ask your doctor).&nbsp;</li><li>If your thyroid gland is not working properly.</li><li>If you have had any repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines.</li><li>If you regularly drink large amounts of alcohol.&nbsp;</li><li>If you are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</li><li>If you take other medicines called fibrates to lower your cholesterol.</li></ul><p>If any of the above applies to you (or you are in doubt), please go back and see your doctor.</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Resova.</p><ul><li>If you have problems with your kidneys.&nbsp;</li><li>If you have problems with your liver.&nbsp;</li><li>If you have had repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines. Tell your doctor immediately if you have unexplained muscle aches or pains, especially if you feel unwell or have a fever. Also, tell your doctor or pharmacist if you have a muscle weakness that is constant. &nbsp;</li><li>If you have or have had myasthenia (a disease with general muscle weakness including in some cases muscles used when breathing), or ocular myasthenia (a disease causing eye muscle weakness) as statins may sometimes aggravate the condition or lead to the occurrence of myasthenia (see section 4).</li><li>If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking Resova or other related medicines.</li><li>If you regularly drink large amounts of alcohol.</li><li>If your thyroid gland is not working properly.&nbsp;</li><li>If you take other medicines called fibrates<strong> </strong>to lower your cholesterol. Please read this leaflet carefully, even if you have taken other medicines for high cholesterol before. &nbsp;</li><li>If you take medicines used to treat the HIV infection e.g. ritonavir with lopinavir and/or atazanavir, please see &ldquo;Other medicines and Resova&rdquo;.&nbsp;</li><li>If you are taking or have taken in the last 7 days a medicine called fusidic acid (a medicine for bacterial infection), orally or by injection. The combination of fusidic acid and rosuvastatin can lead to serious muscle problems (rhabdomyolysis), please see &ldquo;Other medicines and Resova&rdquo;.&nbsp;</li><li>If you are over 70 (as your doctor needs to choose the right start dose of Resova to suit you).&nbsp;</li><li>If you have severe respiratory failure.&nbsp;</li><li>If you are of Asian origin &ndash; that is Japanese, Chinese, Filipino, Vietnamese, Korean and Indian. Your doctor needs to choose the right start dose of Resova to suit you.</li></ul><p>If any of the above applies to you (or if you are not sure):</p><ul><li>Do not take rosuvastatin 40 mg (the highest dose) and check with your doctor or pharmacist before you actually start taking any dose of Resova.</li></ul><p>Serious skin reactions including Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in association with rosuvastatin treatment. Stop using Resova and seek medical attention immediately if you notice any of the symptoms described in section 4.</p><p>In a small number of people, statins can affect the liver. This is identified by a simple test which looks for increased levels of liver enzymes in the blood. For this reason, your doctor will usually carry out this blood test (liver function test) before and during treatment with Resova.</p><p>While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.</p><p><strong>Children and adolescents</strong></p><ul><li>If the patient is under 6 years old: Resova should not be given to children younger than 6 years.&nbsp;</li><li>If the patient is below 18 years of age: Rosuvastatin 40 mg is not suitable for use in children and adolescents below 18 years of age.</li></ul><p><strong>Other medicines and Resova</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Tell your doctor if you are taking any of the following:</p><ul><li>Ciclosporin (used for example, after organ transplants),&nbsp;</li><li>Warfarin, clopidogrel or ticagrelor (or any other drug used for thinning the blood),&nbsp;</li><li>Fibrates (such as gemfibrozil, fenofibrate) or any other medicine used to lower cholesterol (such as ezetimibe),&nbsp;</li><li>Indigestion remedies (used to neutralise acid in your stomach),&nbsp;</li><li>Erythromycin (an antibiotic), fusidic acid (an antibiotic &ndash; please see below and Warnings and precautions),&nbsp;</li><li>An oral contraceptive (the pill),&nbsp;</li><li>Regorafenib (used to treat cancer),</li><li>Darolutamide (used to treat cancer),&nbsp;</li><li>Capmatinib (used to treat cancer),</li><li>Hormone replacement therapy,&nbsp;</li><li>Fostamatinib (used to treat low platelet counts),</li><li>Febuxostat (used to treat and prevent high blood levels of uric acid),</li><li>Teriflunomide (used to treat multiple sclerosis),</li><li>Any of the following drugs used to treat viral infections, including HIV or hepatitis C infection, alone or in combination (please see Warnings and precautions): ritonavir, lopinavir, atazanavir, sofosbuvir, voxilaprevir, ombitasvir, paritaprevir, dasabuvir, velpatasvir, grazoprevir, elbasvir, glecaprevir, pibrentasvir.</li></ul><p>The effects of these medicines could be changed by Resova or they could change the effect of Resova.</p><p>If you need to take oral fusidic acid to treat a bacterial infection you will need to temporarily stop using this medicine. Your doctor will tell you when it is safe to restart Resova. Taking Resova with fusidic acid may rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis). See more information regarding rhabdomyolysis in section 4.</p><p><strong>Pregnancy and breast-feeding</strong><br />Do not take Resova if you are pregnant or breast-feeding. If you become pregnant while taking Resova stop taking it immediately and tell your doctor. Women should avoid becoming pregnant while taking Resova by using suitable contraception.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong><br />Most people can drive a car and operate machinery while using Resova &ndash; it will not affect their ability. However, some people feel dizzy during treatment with Resova. If you feel dizzy, consult your doctor before attempting to drive or use machines.</p><p><strong>Resova contains lactose</strong><br />Resova contains lactose. Each film-coated tablet of Resova 10 mg and 20 mg Film-coated Tablets contains 60 mg lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong><em>Usual doses in adults</em><br />If you are taking Resova for high cholesterol:</strong><br /><em>Starting dose</em><br />Your treatment with rosuvastatin must start with the 5 mg or the 10 mg dose, even if you have taken a higher dose of a different statin before. The choice of your start dose will depend upon:</p><ul><li>Your cholesterol levels. &nbsp;</li><li>The level of risk you have of experiencing a heart attack or stroke. &nbsp;</li><li>Whether you have a factor that may make you more sensitive to possible side effects.</li></ul><p>Please check with your doctor or pharmacist which start dose of Resova will best suit you.</p><p>Your doctor may decide to give you the lowest dose (5 mg) if:</p><ul><li>You are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).&nbsp;</li><li>You are over 70 years of age.&nbsp;</li><li>You have moderate kidney problems.&nbsp;</li><li>You are at risk of muscle aches and pains (myopathy).</li></ul><p><strong>Increasing the dose and maximum daily dose</strong><br />Your doctor may decide to increase your dose. This is so that you are taking the amount of rosuvastatin that is right for you. If you started with a 5 mg dose, your doctor may decide to double this to 10 mg, then 20 mg and then 40 mg if necessary. If you started on 10 mg, your doctor may decide to double this to 20 mg and then 40 mg if necessary. There will be a gap of four weeks between every dose adjustment.</p><p>The maximum daily dose of rosuvastatin is 40 mg. It is only for patients with high cholesterol levels and a high risk of heart attacks or stroke whose cholesterol levels are not lowered enough with 20 mg. &nbsp;</p><p><strong>If you are taking Resova to reduce your risk of having a heart attack, stroke or related health problems:</strong><br />The recommended dose is 20 mg daily. However, your doctor may decide to use a lower dose if you have any of the factors mentioned above. &nbsp;</p><p><strong>Use in children and adolescents aged 6-17 years</strong><br />The dose range in children and adolescents aged 6 to 17 years is 5 to 20 mg once daily. The usual start dose is 5 mg per day, and your doctor may gradually increase your dose to find the right amount of rosuvastatin for you. The maximum daily dose of Resova is 10 or 20 mg for children aged 6 to 17 years depending on your underlying condition being treated. Take your dose once a day. Rosuvastatin 40 mg should not be used by children.</p><p><strong><em>Taking your tablets</em></strong><br />Swallow each tablet whole with a drink of water.</p><p>Take Resova once daily. You can take it at any time of the day with or without food.</p><p>Try to take your tablet at the same time every day to help you to remember it.</p><p><strong>&nbsp;Regular cholesterol checks</strong><br />It is important to go back to your doctor for regular cholesterol checks, to make sure your cholesterol has reached and is staying at the correct level. &nbsp;</p><p>Your doctor may decide to increase your dose so that you are taking the amount of Resova that is right for you.</p><p><strong>&nbsp;If you take more Resova than you should</strong><br />Contact your doctor or nearest hospital for advice.</p><p>If you go into hospital or receive treatment for another condition, tell the medical staff that you&rsquo;re taking Resova.</p><p><strong>If you forget to take Resova</strong><br />Don&rsquo;t worry, just take your next scheduled dose at the correct time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Resova &nbsp;</strong><br />Talk to your doctor if you want to stop taking Resova. Your cholesterol levels might increase again if you stop taking Resova.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>It is important that you are aware of what these side effects may be. They are usually mild and disappear after a short time.</p><p><strong>&nbsp;Stop taking rosuvastatin and seek medical help immediately if you have any of the following allergic reactions: </strong></p><ul><li>Difficulty in breathing, with or without swelling of the face, lips, tongue and/or throat. &nbsp;</li><li>Swelling of the face, lips, tongue and/or throat, which may cause difficulty in swallowing. &nbsp;</li><li>Severe itching of the skin (with raised lumps).</li><li>Reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome).</li><li>Widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome).</li></ul><p><strong>Also, stop taking rosuvastatin and talk to your doctor immediately: </strong></p><ul><li>If you have any unusual aches or pains in your muscles which go on for longer than you might expect. Muscle symptoms are more common in children and adolescents than in adults. As with other statins, a very small number of people have experienced unpleasant muscle effects and rarely these have gone on to become a potentially life threatening muscle damage known as rhabdomyolysis.&nbsp;</li><li>If you experience muscle rupture.&nbsp;</li><li>If you have lupus-like disease syndrome (including rash, joint disorders and effects on blood cells).</li></ul><p><strong>Common possible side effects (these may affect between 1 in 10 and 1 in 100 patients): </strong></p><ul><li>Headache, stomach pain, constipation, feeling sick, muscle pain, feeling weak, dizziness. &nbsp;</li><li>An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your rosuvastatin tablets (only rosuvastatin 40 mg). &nbsp;</li><li>Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine.</li></ul><p><strong>Uncommon possible side effects (these may affect between 1 in 100 and 1 in 1,000 patients): </strong></p><ul><li>Rash, itching or other skin reactions. &nbsp;</li><li>An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your rosuvastatin tablets (only rosuvastatin 5 mg, 10 mg and 20 mg).</li></ul><p><strong>Rare possible side effects (these may affect between 1 in 1,000 and 1 in 10,000 patients): </strong></p><ul><li>Severe allergic reaction &ndash; signs include swelling of the face, lips, tongue and/or throat, difficulty in swallowing and breathing, a severe itching of the skin (with raised lumps). If you think you are having an allergic reaction, then stop taking rosuvastatin and seek medical help immediately.</li><li>Muscle damage in adults &ndash; as a precaution, stop taking rosuvastatin and talk to your doctor immediately if you have any unusual aches or pains in your muscles which go on for longer than expected.&nbsp;</li><li>A severe stomach pain (inflamed pancreas).</li><li>Increase in liver enzymes in the blood.&nbsp;</li><li>Bleeding or bruising more easily than normal due to low level of blood platelets.&nbsp;</li><li>Lupus-like disease syndrome (including rash, joint disorders and effects on blood cells).</li></ul><p><strong>Very rare possible side effects (these may affect less than 1 in 10,000 patients): </strong>&nbsp;</p><ul><li>Jaundice (yellowing of the skin and eyes), hepatitis (an inflamed liver), traces of blood in your urine, damage to the nerves of your legs and arms (such as numbness), joint pain, memory loss and breast enlargement in men (gynaecomastia). &nbsp;</li></ul><p><strong>Side effects of unknown frequency may include: </strong></p><ul><li>Diarrhoea (loose stools), cough, shortness of breath, oedema (swelling), sleep disturbances, including insomnia and nightmares, sexual difficulties, depression, breathing problems, including persistent cough and/or shortness of breath or fever, tendon injury and muscle weakness that is constant.</li><li>Myasthenia gravis (a disease causing general muscle weakness including in some cases muscles used when breathing), Ocular myasthenia (a disease causing eye muscle weakness). Talk to your doctor if you experience weakness in your arms or legs that worsens after periods of activity, double vision or drooping of your eyelids, difficulty swallowing, or shortness of breath.</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is rosuvastatin calcium.</p><p>Each film-coated tablet of Resova 10 mg Film-coated Tablets contains 10.4 mg rosuvastatin calcium equivalent to 10 mg rosuvastatin.</p><p>Each film-coated tablet of Resova 20 mg Film-coated Tablets contains 20.8 mg rosuvastatin calcium equivalent to 20 mg rosuvastatin.</p><p>The other ingredients are: <em>Tablet core:</em> Lactose, calcium phosphate dihydrate, crospovidone, microcrystalline cellulose and magnesium stearate. <em>Tablet coat:</em> Opadry pink.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Resova 10 mg Film-coated Tablets are light pink round film-coated tablets embossed with “JI 141” on one side in PVC/aluminum blisters. 

Resova 20 mg Film-coated Tablets are dark pink round film-coated tablets embossed with “JI 142” on one side in PVC/aluminum blisters. 

Pack size: 30 Film-coated Tablets.  


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder, Batch releaser and Bulk manufacturer</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><p>&bull;&nbsp;Saudi Arabia<br />The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br />&bull;&nbsp;Other GCC States<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2024; version number Un3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي ريسوڤا إلى مجموعة أدوية تسمى الستاتينات.&nbsp;</p><p dir="RTL"><strong>لقد تم وصف ريسوڤا لك للأسباب التالية: </strong></p><ul dir="rtl"><li>تعاني من ارتفاع في مستوى الكوليسترول. وهذا يعني أنك معرض لخطر الإصابة بنوبة قلبية أو سكتة دماغية. يستخدم ريسوڤا لدى البالغين، المراهقين والأطفال بعمر 6 سنوات أو أكبر لعلاج ارتفاع الكوليسترول.&nbsp;</li><li>لقد نُصحت بتناول الستاتين، وذلك لأن تغيير نظامك الغذائي وممارسة المزيد من التمارين الرياضية لم يكونا كافيين لتعديل مستويات الكوليسترول. عليك الاستمرار في اتباع نظامك الغذائي لخفض الكوليسترول وممارسة الرياضة أثناء تناول ريسوڤا.</li></ul><p dir="RTL">أو&nbsp;</p><ul dir="rtl"><li>لديك عوامل أخرى تزيد من خطر إصابتك بنوبة قلبية، سكتة دماغية أو مشاكل صحية ذات صلة.</li></ul><p dir="RTL">قد تحدث النوبة القلبية، السكتة الدماغية وغيرها من المشاكل الصحية بسبب مرض يسمى تصلب الشرايين. يحدث تصلب الشرايين بسبب تراكم الرواسب الدهنية في الشرايين.</p><p dir="RTL"><strong>ما سبب أهمية الاستمرار في تناول ريسوڤا</strong></p><p dir="RTL">يستخدم ريسوڤا لتصحيح مستويات المواد الدهنية في الدم التي تسمى اللبيدات، وأكثرها شيوعاً هو الكوليسترول.&nbsp;</p><p dir="RTL">يوجد أنواع مختلفة من الكوليسترول في الدم - الكوليسترول &rsquo;الضار&lsquo; والكوليسترول &rsquo;النافع&lsquo;.&nbsp;&nbsp;</p><ul dir="rtl"><li>يمكن أن يقلل ريسوڤا من الكوليسترول &rsquo;الضار&lsquo; ويزيد الكوليسترول &rsquo;النافع&lsquo;.&nbsp;</li><li>يعمل عن طريق المساعدة في منع إنتاج الجسم للكوليسترول &rsquo;الضار&lsquo;. كما أنه يحسن قدرة جسمك على إزالته من دمك.</li></ul><p dir="RTL">بالنسبة لمعظم الناس، لا يؤثر ارتفاع الكوليسترول في الطريقة التي يشعرون بها لأنه لا ينتج عنه أي أعراض. ومع ذلك، إذا ترك دون علاج، فقد تتراكم الرواسب الدهنية في جدران الأوعية الدموية مما يؤدي إلى تضييقها.</p><p dir="RTL">في بعض الأحيان، قد يحدث انسداد في هذه الأوعية الدموية الضيقة مما قد يحجب وصول الدم إلى القلب أو الدماغ وهذا يؤدي إلى حدوث نوبة قلبية أو سكتة دماغية. يمكنك تقليل احتمالية إصابتك بنوبة قلبية، سكتة دماغية أو مشاكل صحية ذات صلة عن طريق خفض مستويات الكوليسترول لديك.</p><p dir="RTL">عليك الاستمرار في تناول ريسوڤا، حتى لو وصل الكوليسترول إلى المستوى المناسب، لأنه يمنع مستويات الكوليسترول لديك من الارتفاع مرة أخرى والتسبب في تراكم الرواسب الدهنية. ومع ذلك، يجب أن تتوقف عن تناوله إذا أخبرك طبيبك بذلك، أو إذا أصبحتِ حاملاً</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول </strong><strong>ريسوڤا </strong></p><ul dir="rtl"><li>إذا سبق لك أن عانيت من رد فعل تحسسي تجاه ريسوڤا، أو لأي من مكوناته.&nbsp;</li><li>إذا كنتِ حاملاً أو مرضعاً. توقفي عن تناول ريسوڤا على الفور إذا أصبحت حاملاً أثناء تناوله وأخبري طبيبكِ. يجب على النساء تجنب الحمل أثناء تناول ريسوڤا باستخدام وسائل منع الحمل المناسبة.</li><li>إذا كنت تعاني من مرض في الكبد.&nbsp;</li><li>إذا كنت تعاني من مشاكل شديدة في الكلى.&nbsp;</li><li>إذا كنت تعاني من أوجاع أو آلام متكررة أو غير مبررة في العضلات.&nbsp;</li><li>إذا كنت تتناول مجموعة عقاقير من سوفوسبوڤير/ڤلباتاسڤير/ ڤوكسيلابريڤير (تستخدم للعدوى الفيروسية في الكبد تسمى التهاب الكبد ج).&nbsp;</li><li>إذا كنت تتناول عقاراً يسمى سيكلوسبورين (يستخدم على سبيل المثال، بعد عمليات زرع الأعضاء).</li></ul><p dir="RTL">إذا انطبق عليك أي مما سبق (أو إذا كان لديك شك)، يُرجى زيارة طبيبك وأخذ مشورته.</p><p dir="RTL">بالإضافة إلى ذلك، لا تتناول روسوڤاستاتين 40 ملغم (الجرعة الأعلى):</p><ul dir="rtl"><li>إذا كنت تعاني من مشاكل متوسطة في الكلى (إذا كان لديك شك، يُرجى استشارة طبيبك).&nbsp;</li><li>إذا كانت الغدة الدرقية لديك لا تعمل على نحو طبيعي.</li><li>إذا كنت تعاني من أي أوجاع أو آلام متكررة أو غير مبررة في العضلات، تاريخ شخصي أو عائلي من مشاكل العضلات، أو تاريخ سابق من مشاكل العضلات عند تناول أدوية أخرى لخفض الكوليسترول.</li><li>إذا كنت تشرب كميات كبيرة من الكحول باستمرار.&nbsp;</li><li>إذا كنت من أصل آسيوي (ياباني، صيني، فلبيني، فيتنامي، كوري، وهندي).</li><li>إذا كنت تتناول أدوية أخرى تسمى الفيبرات لخفض نسبة الكوليسترول لديك.</li></ul><p dir="RTL">إذا انطبق عليك أي مما سبق (أو إذا كان لديك شك)، يُرجى زيارة طبيبك وأخذ مشورته.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول ريسوڤا.</p><ul dir="rtl"><li>إذا كنت تعاني من مشاكل في الكلى.&nbsp;</li><li>إذا كنت تعاني من مشاكل في الكبد.&nbsp;</li><li>إذا كنت تعاني من أوجاع أو آلام متكررة أو غير مبررة في العضلات، تاريخ شخصي أو عائلي من مشاكل العضلات، أو تاريخ سابق من مشاكل العضلات عند تناول أدوية أخرى لخفض الكوليسترول. أخبر طبيبك على الفور إذا كنت تعاني من أوجاع أو آلام غير مبررة في العضلات، خصوصاً إذا كنت تشعر بتوعك أو تعاني من حمى. أخبر طبيبك كذلك أو الصيدلي إذا كنت تعاني من ضعف في العضلات بشكل مستمر.&nbsp;</li><li>إذا كنت تعاني أو عانيت في الماضي من وهن عضلي (مرض يصاحبه ضعف عام في العضلات ويشمل في بعض الحالات العضلات المستخدمة عند التنفس)، أو وهن عضلات العين (مرض يسبب ضعف عضلة العين) حيث أن الستاتينات قد تؤدي إلى تفاقم الحالة أو تؤدي إلى حدوث الوهن العضلي (انظر القسم 4).</li><li>إذا كنت قد أصبت في أي وقت سابق بطفح جلدي شديد أو تقشير جلدي، تبثر و/أو تقرحات في الفم بعد تناول ريسوڤا أو الأدوية الأخرى ذات الصلة.</li><li>إذا كنت تشرب كميات كبيرة من الكحول باستمرار.</li><li>إذا كانت الغدة الدرقية لديك لا تعمل على نحو طبيعي.&nbsp;</li><li>إذا كنت تتناول أدوية أخرى تسمى الفيبرات<strong> </strong>لخفض نسبة الكوليسترول. يُرجى قراءة هذه النشرة بعناية، حتى لو كنت قد تناولت أدوية أخرى لعلاج ارتفاع الكوليسترول من قبل.&nbsp;</li><li>إذا كنت تتناول الأدوية المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية، مثل ريتوناڤير مع لوبيناڤير و/أو أتازاناڤير، يُرجى النظر إلى &quot;الأدوية الأخرى وريسوڤا&quot;.&nbsp;</li><li>إذا كنت تتناول أو قد تناولت في السبعة أيام الماضية دواءً يُسمى حمض الفوسيديك (دواء لعلاج العدوى البكتيرية)، عن طريق الفم أو الحقن. يمكن أن يؤدي الجمع بين حمض الفوسيديك وروسوڤاستاتين إلى حدوث مشاكل خطيرة في العضلات (انحلال الربيدات)، يُرجى النظر إلى &quot;الأدوية الأخرى وريسوڤا&quot;.&nbsp;</li><li>إذا كان عمرك أكثر من 70 عاماً (حيث يحتاج طبيبك إلى اختيار جرعة البدء الصحيحة من ريسوڤا التي تناسبك).</li><li>إذا كنت تعاني من فشل تنفسي شديد.&nbsp;</li><li>إذا كنت من أصل آسيوي - أي ياباني، صيني، فلبيني، فيتنامي، كوري، وهندي. يحتاج طبيبك إلى اختيار جرعة البدء الصحيحة من ريسوڤا التي تناسبك.</li></ul><p dir="RTL">إذا انطبق عليك أي مما سبق (أو إذا لم تكن متأكداً):</p><ul dir="rtl"><li>لا تتناول روسوڤاستاتين 40 ملغم (الجرعة الأعلى) واستشر طبيبك أو الصيدلي قبل أن تبدأ فعلياً في تناول أي جرعة من ريسوڤا.</li></ul><p dir="RTL">تم الإبلاغ عن تفاعلات جلدية خطيرة بما في ذلك متلازمة ستيفنز جونسون والتفاعل الدوائي مع كثرة الحمضات والأعراض الجهازية المرتبطة مع علاج روسوڤاستاتين. توقف عن استخدام ريسوڤا واطلب العناية الطبية على الفور إذا لاحظت أياً من الأعراض الموضحة في القسم 4.</p><p dir="RTL">يمكن أن تؤثر الستاتينات على الكبد في عدد قليل من الأشخاص. يتم تحديد ذلك من خلال اختبار بسيط لمعرفة زيادة مستويات إنزيمات الكبد في الدم. ولهذا السبب، سيجري طبيبك عادةً اختبار الدم هذا (اختبار وظائف الكبد) قبل وأثناء العلاج باستخدام ريسوڤا.</p><p dir="RTL">أثناء تناولك لهذا الدواء، سيقوم طبيبك بمراقبة حالتك عن كثب إذا كنت مصاباً بمرض السكري أو تكون عرضة لخطر الإصابة بمرض السكري. من المحتمل أن تكون عرضة لخطر الإصابة بمرض السكري إذا كان لديك مستويات عالية من السكريات والدهون في دمك، وإذا كنت تعاني من زيادة الوزن وارتفاع ضغط الدم.</p><p dir="RTL"><strong>الأطفال</strong> <strong>والمراهقون</strong></p><ul dir="rtl"><li>إذا كان عمر المريض أقل من 6 أعوام: يجب عدم إعطاء ريسوڤا إلى الأطفال الذين تقل أعمارهم عن 6 أعوام.&nbsp;</li><li>إذا كان عمر المريض أقل من 18 عاماً: روسوڤاستاتين 40 ملغم غير مناسب للأطفال والمراهقين الذين تقل أعمارهم عن 18 عاماً.</li></ul><p dir="RTL"><strong>الأدوية الأخرى </strong><strong>وريسوڤا</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أياً مما يلي:</p><ul dir="rtl"><li>سيكلوسبورين (يستخدم على سبيل المثال، بعد زراعة الأعضاء)،&nbsp;</li><li>وارفارين، كلوبيدوجريل أو تيكاجريلور (أو أي دواء آخر يستخدم لترقيق الدم)،&nbsp;</li><li>الفيبرات (مثل جمفيبروزيل، فينوفيبرات) أو أي دواء آخر يستخدم لخفض الكوليسترول (مثل إزيتمايب)،&nbsp;</li><li>علاجات عسر الهضم (المستخدمة لمعادلة الحمض في المعدة)،</li><li>إريثروميسين (مضاد حيوي)، حمض الفوسيديك (مضاد حيوي - يُرجى الاطلاع أدناه والاطلاع على الاحتياطات والتحذيرات)،&nbsp;</li><li>وسائل منع الحمل التي تؤخذ عن طريق الفم (حبوب منع الحمل).&nbsp;</li><li>ريجورافينيب (يستخدم لعلاج السرطان)،</li><li>دارولوتاميد (يستخدم لعلاج السرطان)،&nbsp;</li><li>الكابماتينيب (يستخدم لعلاج السرطان)،&nbsp;</li><li>العلاج الهرموني البديل،&nbsp;</li><li>فوستاماتينيب (يستخدم لعلاج انخفاض عدد الصفائح الدموية)،&nbsp;</li><li>فيبوكسوستات (يستخدم لعلاج ومنع ارتفاع مستويات حمض اليوريك في الدم)،</li><li>تيريفلونومايد (يستخدم لعلاج التصلب المتعدد)،</li><li>أي من الأدوية التالية المستخدم لعلاج حالات العدوى الفيروسية، بما في ذلك عدوى فيروس نقص المناعة البشرية أو التهاب الكبد ج، كل على حدة أو مجتمعة (يُرجى الاطلاع على الاحتياطات والتحذيرات): ريتوناڤير، لوبيناڤير، أتازاناڤير، سوفوسبوڤير، فوكسيلابريڤير، أمبيتاسڤير، باريتابريڤير، داسابوڤير، ڤيلباتاسڤير، غرازوبريڤير الباسڤير، جليكابريڤير، بيبرنتاسڤير.</li></ul><p dir="RTL">قد يغير ريسوڤا تأثير هذه الأدوية أو قد تغير هذه الأدوية تأثير ريسوڤا.</p><p dir="RTL">إذا كنت بحاجة إلى تناول حمض الفيوسيديك عن طريق الفم لعلاج عدوى بكتيرية، سيتعين عليك إيقاف تناول هذا الدواء مؤقتاً. سيُخبرك طبيبك عندما يكون من الآمن إعادة بدء تناول ريسوڤا. نادراً ما يؤدي تناول ريسوڤا مع حمض الفيوسيديك إلى ضعف العضلات، الإيلام أو الألم بها (انحلال الربيدات). تعرف على المزيد من المعلومات عن انحلال الربيدات في القسم 4.</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">لا تتناولين ريسوڤا إذا كنت حاملاً أو ترضعين طبيعياً. توقفي عن تناول ريسوڤا على الفور إذا أصبحت حاملاً أثناء تناوله وأخبري طبيبكِ. يجب على النساء تجنب الحمل أثناء تناول ريسوڤا باستخدام وسائل منع الحمل المناسبة.</p><p dir="RTL">اطلبي النصيحة من طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن لمعظم الناس قيادة السيارة وتشغيل الآلات خلال فترة تناول ريسوڤا - حيث إن تناول الدواء لن يؤثر على قدرتهم على فعل ذلك. ومع ذلك، يشعر بعض الأشخاص بالدوار أثناء تناول ريسوڤا. إذا شعرت بالدوار، استشر طبيبك قبل محاولة القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>يحتوي ريسوڤا على اللاكتوز</strong></p><p dir="RTL">يحتوي ريسوڤا على اللاكتوز. يحتوي كل قرص مغطى بطبقة رقيقة من ريسوڤا 10 و20 ملغم أقراص مغطاة بطبقة رقيقة على 60 ملغم لاكتوز. إذا أخبرك طبيبك أن لديك عدم تحمل تجاه بعض السكريات، تواصل مع طبيبك قبل تناول هذا المستحضر الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول دوائك كما أخبرك طبيبك. تحقق من طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL"><strong><em>الجرعات المعتادة عند البالغين </em></strong></p><p dir="RTL"><strong>إذا كنت تتناول ريسوڤا لعلاج ارتفاع الكوليسترول: </strong></p><p dir="RTL"><em>جرعة البداية </em></p><p dir="RTL">يجب أن يبدأ علاجك بروسوڤاستاتين بجرعة 5 ملغم أو 10 ملغم، حتى لو كنت قد تناولت جرعة أعلى من ستاتين مختلف من قبل. سوف يعتمد اختيار جرعة البداية على:</p><ul dir="rtl"><li>مستويات الكوليسترول لديك.&nbsp;</li><li>مستوى احتمالية تعرضك لنوبة قلبية أو سكتة دماغية.&nbsp;</li><li>ما إذا كان لديك عامل قد يجعلك أكثر حساسية للآثار الجانبية المحتملة.</li></ul><p dir="RTL">يُرجى مراجعة طبيبك أو الصيدلي لمعرفة أي جرعة بداية من ريسوڤا سوف تناسبك بشكل أفضل.</p><p dir="RTL">قد يقرر طبيبك إعطائك الجرعة الأقل (5 ملغم) إذا:</p><ul dir="rtl"><li>كنت من أصل آسيوي (ياباني، صيني، فلبيني، فيتنامي، كوري وهندي).&nbsp;</li><li>كان عمرك أكثر من 70 عاماً.&nbsp;</li><li>كنت تعاني من مشاكل متوسطة في الكلى.&nbsp;</li><li>كنت معرض لخطر الإصابة بأوجاع وآلام في العضلات (اعتلال عضلي).</li></ul><p dir="RTL"><strong>زيادة الجرعة والجرعة اليومية القصوى </strong></p><p dir="RTL">قد يقرر طبيبك زيادة جرعتك. وذلك حتى تتمكن من تناول كمية روسوڤاستاتين المناسبة لك. إذا بدأت بجرعة 5 ملغم، فقد يقرر طبيبك مضاعفة هذه الجرعة إلى 10 ملغم، ثم 20 ملغم ثم 40 ملغم إذا لزم الأمر. إذا بدأت بجرعة 10 ملغم، فقد يقرر طبيبك مضاعفة الجرعة إلى 20 ملغم ثم 40 ملغم إذا لزم الأمر. وسوف يكون هناك فترة أربعة أسابيع بين كل تعديل للجرعة.</p><p dir="RTL">الجرعة اليومية القصوى من روسوڤاستاتين هي 40 ملغم. تلك الجرعة مخصصة فقط للمرضى الذين يعانون من ارتفاع مستويات الكوليسترول وارتفاع خطر الإصابة بالنوبات القلبية أو السكتة الدماغية ولا تنخفض مستويات الكوليسترول لديهم بما يكفي عند تناول جرعة 20 ملغم.&nbsp;</p><p dir="RTL"><strong>إذا كنت تتناول ريسوڤا لتقليل خطر الإصابة بنوبة قلبية، سكتة دماغية أو م</strong><strong>شاكل</strong><strong> صحية ذات صلة: </strong></p><p dir="RTL">الجرعة الموصى بها هي 20 ملغم يومياً. ومع ذلك، قد يقرر طبيبك استخدام جرعة أقل إذا كان لديك أي من العوامل المذكورة أعلاه.&nbsp;</p><p dir="RTL"><strong>الاستخدام لدى الأطفال والمراهقين الذين تتراوح أعمارهم بين 6-17 عاماً </strong></p><p dir="RTL">تتراوح الجرعة عند الأطفال والمراهقين الذين تتراوح أعمارهم بين 6 إلى 17 عاماً هي 5 إلى 20 ملغم مرة واحدة يومياً. جرعة البداية المعتادة هي 5 ملغم في اليوم، وقد يزيد طبيبك جرعتك تدريجياً للوصول إلى الكمية المناسبة لك من روسوڤاستاتين. الجرعة اليومية القصوى من ريسوڤا هي 10 أو 20 ملغم للأطفال الذين تتراوح أعمارهم بين 6 إلى 17 عاماً اعتماداً على الحالة الأساسية التي يتم علاجها. خذ جرعتك مرة واحدة في اليوم. يجب ألا يتناول الأطفال روسوڤاستاتين 40 ملغم.</p><p dir="RTL"><strong><em>تناول أقراصك </em></strong></p><p dir="RTL">ابتلع كل قرص بالكامل مع شرب مقدار من الماء.</p><p dir="RTL">تناول ريسوڤا مرة واحدة في اليوم. يمكنك تناوله في أي وقت من اليوم مع طعام أو بدونه.</p><p dir="RTL">حاول أن تتناول قرصك في الوقت ذاته من كل يوم لمساعدتك على تذكر تناوله.</p><p dir="RTL"><strong>فحوصات الكوليسترول المنتظمة </strong></p><p dir="RTL">من المهم الرجوع إلى طبيبك لإجراء فحوصات الكوليسترول المنتظمة، للتأكد من وصول الكوليسترول لديك إلى المستوى الصحيح وبقائه كذلك.&nbsp;</p><p dir="RTL">قد يقرر طبيبك زيادة جرعتك حتى تأخذ كمية ريسوڤا المناسبة لك.</p><p dir="RTL"><strong>إذا تناولت ريسوڤا أكثر من اللازم</strong></p><p dir="RTL">اتصل بطبيبك أو أقرب مستشفى للحصول على المشورة. إذا ذهبت إلى المستشفى أو تلقيت علاجاً لحالة أخرى، فأخبر الطاقم الطبي أنك تتناول ريسوڤا.</p><p dir="RTL"><strong>إذا نسيت تناول</strong><strong> ريسوڤا</strong></p><p dir="RTL">لا تقلق، ما عليك إلا تناول جرعتك التالية المحددة في الوقت الصحيح. لا تقم بتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>إذا توقفت عن تناول </strong><strong>ريسوڤا&nbsp; </strong></p><p dir="RTL">تحدث مع طبيبك إذا كنت تريد التوقف عن تناول ريسوڤا. قد ترتفع مستويات الكوليسترول مرة أخرى إذا توقفت عن تناول ريسوڤا.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل الطبيب أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">من المهم أن تكون على دراية بالآثار الجانبية المحتملة التي قد تحدث. عادة ما تكون خفيفة وتختفي بعد وقت قصير.</p><p dir="RTL"><strong>توقف عن تناول روسوڤاستاتين واطلب المساعدة الطبية على الفور إذا ظهرت لديك أي من ردود الفعل التحسسية التالية: </strong></p><ul dir="rtl"><li>صعوبة في التنفس، مع أو بدون تورم الوجه، الشفتين، اللسان و/أو الحلق.&nbsp;</li><li>تورم الوجه، الشفتين، اللسان و/أو الحلق، مما قد يؤدي إلى صعوبة في البلع.&nbsp;</li><li>حكة شديدة في الجلد (مع وجود كتل بارزة).</li><li>بقع حمراء غير بارزة، شبيهة بالهدف أو دائرية على الجسم، تكون غالباً مع بثور مركزية، تقشر الجلد، تقرحات في الفم، الحلق، الأنف، الأعضاء التناسلية والعينين. يمكن أن يسبق هذا الطفح الجلدي الخطير حمى وأعراض تشبه الانفلونزا (متلازمة ستيفنز جونسون).</li><li>طفح واسع الانتشار، ارتفاع درجة حرارة الجسم وتضخم الغدد الليمفاوية (متلازمة التفاعل الدوائي مع كثرة الحمضات والأعراض الجهازية أو متلازمة فرط الحساسية للأدوية).</li></ul><p dir="RTL"><strong>توقف أيضاً عن تناول روسوڤاستاتين وتحدث مع طبيبك على الفور: </strong></p><ul dir="rtl"><li>إذا كنت تعاني من أي أوجاع أو آلام غير عادية في عضلاتك تستمر لفترة أطول مما تتوقع. تكون أعراض العضلات أكثر شيوعاً لدى الأطفال والمراهقين من البالغين. كما هو الحال مع أدوية الستاتينات الأخرى، عانى عدد قليل جداً من الأشخاص من تأثيرات عضلية مزعجة ونادراً ما تطورت هذه التأثيرات إلى تلف عضلي محتمل يهدد الحياة يُعرف باسم انحلال الربيدات.&nbsp;</li><li>إذا كنت تعاني من تمزق العضلات.&nbsp;</li><li>إذا كنت تعاني من متلازمة المرض الشبيه بالذئبة (بما في ذلك الطفح، اضطرابات المفاصل والتأثيرات على خلايا الدم).</li></ul><p dir="RTL"><strong>الآثار الجانبية المحتملة الشائعة (قد تؤثر في مريض واحد من بين كل 10 مرضى ومريض واحد من بين كل 100 مريض): </strong></p><ul dir="rtl"><li>صداع، ألم في المعدة، إمساك، شعور بالإعياء، ألم عضلي، شعور بالضعف، دوخة.&nbsp;</li><li>زيادة كمية البروتين في البول - عادة ما يعود هذا إلى طبيعته من تلقاء نفسه دون الحاجة إلى التوقف عن تناول أقراص روسوڤاستاتين (يحدث فقط مع روسوڤاستاتين بتركيز 40 ملغم).&nbsp;</li><li>مرض السكري. تزداد احتمالية الإصابة به إذا كان لديك مستويات عالية من السكريات والدهون في دمك، وإذا كنت تعاني من زيادة الوزن وارتفاع ضغط الدم. سيراقب طبيبك حالتك الصحية أثناء تناولك هذا الدواء.</li></ul><p dir="RTL"><strong>الآثار الجانبية المحتملة غير الشائعة (قد تؤثر في مريض واحد من بين كل 100 مريض ومريض واحد من بين كل 1000 مريض): </strong></p><ul dir="rtl"><li>طفح، حكة أو تفاعلات جلدية أخرى.&nbsp;</li><li>زيادة كمية البروتين في البول - عادة ما يعود هذا إلى طبيعته من تلقاء نفسه دون الحاجة إلى التوقف عن تناول أقراص روسوڤاستاتين (يحدث فقط مع روسوڤاستاتين بتركيز 5 ملغم، 10 ملغم و20 ملغم).</li></ul><p dir="RTL"><strong>الآثار الجانبية المحتملة النادرة (قد تؤثر في مريض واحد من بين كل 1000 مريض ومريض واحد من بين كل 10000 مريض): </strong></p><ul dir="rtl"><li>رد فعل تحسسي شديد - تشمل العلامات تورم في الوجه، الشفتين، اللسان و/أو الحلق، صعوبة في البلع والتنفس، حكة شديدة في الجلد (مع وجود كتل بارزة). إذا كنت تعتقد أنك تعاني من رد فعل تحسسي، فتوقف عن تناول الروسوڤاستاتين واطلب المساعدة الطبية على الفور.</li><li>تلف العضلات عند البالغين - كإجراء احترازي، توقف عن تناول روسوڤاستاتين وتحدث مع طبيبك على الفور إذا كنت تعاني من أي أوجاع أو آلام غير عادية في عضلاتك تستمر لفترة أطول من المتوقع.&nbsp;</li><li>ألم شديد في المعدة (التهاب البنكرياس).</li><li>ارتفاع إنزيمات الكبد في الدم.&nbsp;</li><li>نزف أو تكدم بشكل أسهل من الطبيعي بسبب انخفاض مستوى الصفيحات الدموية.&nbsp;</li><li>متلازمة المرض الشبيه بالذئبة (بما في ذلك الطفح، اضطرابات المفاصل والتأثيرات على خلايا الدم).</li></ul><p><strong>آثار جانبية محتملة نادرة جداً (قد تؤثر في أقل من 1 من بين كل 10000 مريض): </strong>&nbsp;</p><ul dir="rtl"><li>يرقان (اصفرار الجلد والعينين)، التهاب الكبد (التهاب في الكبد)، آثار دم في البول، تلف أعصاب ساقيك وذراعيك (مثل التنميل)، آلام المفاصل، فقدان الذاكرة وتضخم الثدي عند الرجال (التثدي).&nbsp;</li></ul><p dir="RTL"><strong>قد تشمل الآثار الجانبية غير معروفة التكرار ما يلي: </strong></p><ul dir="rtl"><li>إسهال (براز رخو)، سعال، ضيق في التنفس، وذمة (تورم)، اضطرابات في النوم، تشمل الأرق والكوابيس، مشاكل جنسية، اكتئاب، مشاكل التنفس، بما في ذلك السعال المستمر و/أو ضيق التنفس أو الحمى، إصابة الأوتار وضعف العضلات المستمر.</li><li>وهن عضلي (مرض يسبب ضعف عام في العضلات ويشمل في بعض الحالات العضلات المستخدمة عند التنفس)، وهن عضلات العين (مرض يسبب ضعف عضلة العين). تحدث مع الطبيب إذا كنت تعاني من ضعف في ذراعيك أو ساقيك والذي يتفاقم بعد فترات من النشاط، رؤية مزدوجة أو تدلي الجفون، صعوبة في البلع، أو ضيق في التنفس.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي كالسيوم الروسوڤاستاتين.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من ريسوڤا 10 ملغم أقراص مغطاة بطبقة رقيقة على 10.4 ملغم كالسيوم الروسوڤاستاتين يكافئ 10 ملغم روسوڤاستاتين.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من ريسوڤا 20 ملغم أقراص مغطاة بطبقة رقيقة على 20.8 ملغم كالسيوم الروسوڤاستاتين يكافئ 20 ملغم روسوڤاستاتين.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي: <em>لب القرص:</em> لاكتوز، فوسفات الكالسيوم ثنائي الماء، كروسبوڤيدون، سيلليلوز بلوري مكروي وستيرات المغنيسيوم. <em>غلاف القرص:</em> أوبادري وردي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ريسوڤا 10 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص لونها وردي فاتح ودائرية الشكل مغطاة بطبقة رقيقة منقوش على أحد جانبيها &quot;JI 141&quot; في أشرطة من كلوريد متعدد الڤينيل/الألومنيوم.</p><p dir="RTL">ريسوڤا 20 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص لونها وردي غامق ودائرية الشكل مغطاة بطبقة رقيقة منقوش على أحد جانبيها &quot;JI 142&quot; في أشرطة من كلوريد متعدد الڤينيل/الألومنيوم.</p><p dir="RTL">حجم العبوة: 30 قرص مغطى بطبقة رقيقة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق، محرر التشغيلة والشركة المصنعة للمستحضر النهائي</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه).&nbsp; من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى</p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 01/2024؛ رقم النسخة Un3.0.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Resova 20 mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 20.8 mg rosuvastatin calcium equivalent to 20 mg rosuvastatin. 

Excipient with known effect: Lactose. 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets.

Dark pink round film-coated tablets embossed with “JI 142” on one side. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Treatment of hypercholesterolaemia</strong></p><p>Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.</p><p>Adults, adolescents and children aged 6 years or older with homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.</p><p><strong>Prevention of Cardiovascular Events</strong></p><p>Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualised according to the goal of therapy and patient response, using current consensus guidelines.</p><p>Resova may be given at any time of day, with or without food.</p><p><strong>Treatment of hypercholesterolaemia</strong></p><p>The recommended start dose is 5 or 10 mg orally once daily in both statin na&iuml;ve or patients switched from another HMG CoA reductase inhibitor. The choice of start dose should take into account the individual patient&#39;s cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions (see below). A dose adjustment to the next dose level can be made after 4 weeks, if necessary (see section 5.1). In light of the increased reporting rate of adverse reactions with the 40 mg dose compared to lower doses (see section 4.8), a final titration to the maximum dose of 40 mg should only be considered in patients with severe hypercholesterolaemia at high cardiovascular risk (in particular those with familial hypercholesterolaemia), who do not achieve their treatment goal on 20 mg, and in whom routine follow-up will be performed (see section 4.4). Specialist supervision is recommended when the 40 mg dose is initiated.</p><p><strong>Prevention of cardiovascular events</strong></p><p>In the cardiovascular events risk reduction study, the dose used was 20 mg daily (see section 5.1).</p><p><strong>Paediatric population</strong></p><p>Paediatric use should only be carried out by specialists.</p><p><u>Children and adolescents 6 to 17 years of age (Tanner Stage &lt;II-V)</u></p><p><em>Heterozygous familial hypercholesterolaemia</em></p><p>In children and adolescents with heterozygous familial hypercholesterolaemia the usual start dose is 5 mg daily.</p><ul><li>In children 6 to 9 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-10 mg orally once daily. Safety and efficacy of doses greater than 10 mg have not been studied in this population.</li><li>In children 10 to 17 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-20 mg orally once daily. Safety and efficacy of doses greater than 20 mg have not been studied in this population.</li></ul><p>Titration should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations (see section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.</p><p><em>Homozygous familial hypercholesterolaemia</em></p><p>In children 6 to 17 years of age with homozygous familial hypercholesterolaemia, the recommended maximum dose is 20 mg once daily.</p><p>A starting dose of 5 to 10 mg once daily depending on age, weight and prior statin use is advised. Titration to the maximum dose of 20 mg once daily should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations (see section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.</p><p>There is limited experience with doses other than 20 mg in this population.</p><p>The 40 mg tablet is not suitable for use in paediatric patients.</p><p><u>Children younger than 6 years</u></p><p>The safety and efficacy of use in children younger than 6 years has not been studied. Therefore, rosuvastatin is not recommended for use in children younger than 6 years.</p><p><strong>Use in the elderly</strong></p><p>A start dose of 5 mg is recommended in patients &gt;70 years (see section 4.4). No other dose adjustment is necessary in relation to age.</p><p><strong>Dosage in patients with renal insufficiency</strong></p><p>No dose adjustment is necessary in patients with mild to moderate renal impairment. The recommended start dose is 5 mg in patients with moderate renal impairment (creatinine clearance &lt;60 ml/min). The 40 mg dose is contraindicated in patients with moderate renal impairment. The use of Resova in patients with severe renal impairment is contraindicated for all doses (see sections 4.3 and 5.2).</p><p><strong>Dosage in patients with hepatic impairment</strong></p><p>There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, increased systemic exposure has been observed in subjects with Child-Pugh scores of 8 and 9 (see section 5.2). In these patients an assessment of renal function should be considered (see section 4.4). There is no experience in subjects with Child-Pugh scores above 9. Rosuvastatin is contraindicated in patients with active liver disease (see section 4.3).</p><p><strong>Race</strong></p><p>Increased systemic exposure has been seen in Asian subjects (see sections 4.3, 4.4 and 5.2). The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is contraindicated in these patients.</p><p><strong>Genetic polymorphisms</strong></p><p>Specific types of genetic polymorphisms are known that can lead to increased rosuvastatin exposure (see section 5.2). For patients who are known to have such specific types of polymorphisms, a lower daily dose of Resova is recommended.</p><p><strong>Dosage in patients with pre-disposing factors to myopathy</strong></p><p>The recommended start dose is 5 mg in patients with predisposing factors to myopathy (see section 4.4).</p><p>The 40 mg dose is contraindicated in some of these patients (see section 4.3).</p><p><strong>Concomitant therapy</strong></p><p>Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of myopathy (including rhabdomyolysis) is increased when rosuvastatin is administered concomitantly with certain medicinal products that may increase the plasma concentration of rosuvastatin due to interactions with these transporter proteins (e.g. ciclosporin and certain protease inhibitors including combinations of ritonavir with atazanavir, lopinavir and/or tipranavir; see sections 4.4 and 4.5). Whenever possible, alternative medications should be considered, and, if necessary, consider temporarily discontinuing Resova therapy. In situations where co-administration of these medicinal products with Resova is unavoidable, the benefit and the risk of concurrent treatment and Resova dosing adjustments should be carefully considered (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Resova is contraindicated:
• In patients with hypersensitivity to rosuvastatin or to any of the excipients. 
• In patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 times the upper limit of normal (ULN). 
• In patients with severe renal impairment (creatinine clearance <30 ml/min). 
• In patients with myopathy. 
• In patients receiving concomitant combination of sofosbuvir/velpatasvir/voxilaprevir (see section 4.5).
• In patients receiving concomitant ciclosporin. 
• During pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures.

The 40 mg dose is contraindicated in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:
• Moderate renal impairment (creatinine clearance < 60 ml/min) 
• Hypothyroidism 
• Personal or family history of hereditary muscular disorders 
• Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate 
• Alcohol abuse 
• Situations where an increase in plasma levels may occur 
• Asian patients 
• Concomitant use of fibrates.
(See sections 4.4, 4.5 and 5.2)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Renal Effects</strong></p><p>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of rosuvastatin, in particular 40 mg, where it was transient or intermittent in most cases. Proteinuria has not been shown to be predictive of acute or progressive renal disease (see section 4.8). The reporting rate for serious renal events in post-marketing use is higher at the 40 mg dose. An assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40 mg.</p><p><strong>Skeletal Muscle Effects</strong></p><p>Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been reported in rosuvastatin-treated patients with all doses and in particular with doses &gt; 20 mg. Very rare cases of rhabdomyolysis have been reported with the use of ezetimibe in combination with HMG-CoA reductase inhibitors. A pharmacodynamic interaction cannot be excluded (see section 4.5) and caution should be exercised with their combined use. As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis associated with rosuvastatin in post-marketing use is higher at the 40 mg dose.</p><p><em>Creatine Kinase Measurement</em></p><p>Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of a plausible alternative cause of CK increase which may confound interpretation of the result. If CK levels are significantly elevated at baseline (&gt;5xULN) a confirmatory test should be carried out within 5 &ndash; 7 days. If the repeat test confirms a baseline CK &gt;5xULN, treatment should not be started.</p><p><em>Before Treatment</em></p><p>Rosuvastatin, as with other HMG-CoA reductase inhibitors, should be prescribed with caution in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:</p><ul><li>Renal impairment</li><li>Hypothyroidism</li><li>Personal or family history of hereditary muscular disorders</li><li>Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate</li><li>Alcohol abuse</li><li>Age &gt;70 years</li><li>Situations where an increase in plasma levels may occur (see sections 4.2, 4.5 and 5.2)</li><li>Concomitant use of fibrates.</li></ul><p>In such patients the risk of treatment should be considered in relation to possible benefit and clinical monitoring is recommended. If CK levels are significantly elevated at baseline (&gt;5xULN) treatment should not be started.</p><p><em>Whilst on Treatment</em></p><p>Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately, particularly if associated with malaise or fever. CK levels should be measured in these patients. Therapy should be discontinued if CK levels are markedly elevated (&gt;5xULN) or if muscular symptoms are severe and cause daily discomfort (even if CK levels are &le;5xULN). If symptoms resolve and CK levels return to normal, then consideration should be given to re-introducing rosuvastatin or an alternative HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels in asymptomatic patients is not warranted. There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with statins, including rosuvastatin. IMNM is clinically characterised by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.</p><p>In few cases, statins have been reported to induce de novo or aggravate pre-existing myasthenia gravis or ocular myasthenia (see section 4.8). Crestor should be discontinued in case of aggravation of symptoms. Recurrences when the same or a different statin was (re-) administered have been reported.</p><p>In clinical trials, there was no evidence of increased skeletal muscle effects in the small number of patients dosed with rosuvastatin and concomitant therapy. However, an increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors together with fibric acid derivatives including gemfibrozil, ciclosporin, nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when given concomitantly with some HMG-CoA reductase inhibitors. Therefore, the combination of rosuvastatin and gemfibrozil is not recommended. The benefit of further alterations in lipid levels by the combined use of rosuvastatin with fibrates or niacin should be carefully weighed against the potential risks of such combinations. The 40 mg dose is contraindicated with concomitant use of a fibrate (see sections 4.5 and 4.8).</p><p>Rosuvastatin must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). Patients should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness. Statin therapy may be re-introduced seven days after the last dose of fusidic acid. In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g. for the treatment of severe infections, the need for co-administration of rosuvastatin and fusidic acid should only be considered on a case by case basis and under close medical supervision.</p><p>rosuvastatin should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures).</p><p><strong>Severe Cutaneous Adverse Reactions</strong></p><p>Severe cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life-threatening or fatal, have been reported with rosuvastatin (see section 4.8). At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions and be closely monitored. If signs and symptoms suggestive of this reaction appear, Resova should be discontinued immediately and an alternative treatment should be considered.</p><p>If the patient has developed a serious reaction such as SJS or DRESS with the use of Resova, treatment with Resova must not be restarted in this patient at any time.</p><p><strong>Liver Effects</strong></p><p>As with other HMG-CoA reductase inhibitors, rosuvastatin should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease.</p><p>It is recommended that liver function tests be carried out prior to, and 3 months following, the initiation of treatment. Rosuvastatin should be discontinued or the dose reduced if the level of serum transaminases is greater than 3 times the upper limit of normal. The reporting rate for serious hepatic events (consisting mainly of increased hepatic transaminases) in post-marketing use is higher at the 40 mg dose.</p><p>In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with Resova.</p><p><strong>Race</strong></p><p>Pharmacokinetic studies show an increase in exposure in Asian subjects compared with Caucasians (see sections 4.2, 4.3 and 5.2).</p><p><strong>Protease Inhibitors</strong></p><p>Increased systemic exposure to rosuvastatin has been observed in subjects receiving rosuvastatin concomitantly with various protease inhibitors in combination with ritonavir. Consideration should be given both to the benefit of lipid lowering by use of rosuvastatin in HIV patients receiving protease inhibitors and the potential for increased rosuvastatin plasma concentrations when initiating and up titrating rosuvastatin doses in patients treated with protease inhibitors. The concomitant use with certain protease inhibitors is not recommended unless the dose of rosuvastatin is adjusted. (See sections 4.2 and 4.5).</p><p><strong>Lactose Intolerance</strong></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p><strong>Interstitial Lung Disease</strong></p><p>Exceptional cases of interstitial lung disease have been reported with some statins, especially with long-term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p><strong>Diabetes Mellitus</strong></p><p>Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/l, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.</p><p>In the JUPITER study, the reported overall frequency of diabetes mellitus was 2.8% in rosuvastatin and 2.3% in placebo, mostly in patients with fasting glucose 5.6 to 6.9 mmol/l.</p><p><strong>Paediatric Population</strong></p><p>The evaluation of linear growth (height), weight, BMI (body mass index), and secondary characteristics of sexual maturation by Tanner staging in paediatric patients 6 to 17 years of age taking rosuvastatin is limited to a two-year period. After two years of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see section 5.1).</p><p>In a clinical trial of children and adolescents receiving rosuvastatin for 52 weeks, CK elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently compared to observations in clinical trials in adults (see section 4.8).</p><p><strong>Resova contains lactose</strong></p><p>Resova contains lactose. Each film-coated tablet of Resova 20 mg Film-coated Tablets contains 60 mg lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Effect of co-administered medicinal products on rosuvastatin</em></strong></p><p>Transporter protein inhibitors:&nbsp;Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of rosuvastatin with medicinal products that are inhibitors of these transporter proteins may result in increased rosuvastatin plasma concentrations and an increased risk of myopathy (see sections 4.2, 4.4 and 4.5 Table 1).</p><p><em>Ciclosporin:</em>&nbsp;During concomitant treatment with rosuvastatin and ciclosporin, rosuvastatin AUC values were on average 7 times higher than those observed in healthy volunteers (see Table 1). rosuvastatin is contraindicated in patients receiving concomitant ciclosporin (see section 4.3). Concomitant administration did not affect plasma concentrations of ciclosporin.</p><p><em>Protease inhibitors:</em>&nbsp;Although the exact mechanism of interaction is unknown, concomitant protease inhibitor use may strongly increase rosuvastatin exposure (see Table 1). For instance, in a pharmacokinetic study, co-administration of 10 mg rosuvastatin and a combination product of two protease inhibitors (300 mg atazanavir/100 mg ritonavir) in healthy volunteers was associated with an approximately three-fold and seven-fold increase in rosuvastatin AUC and C<sub>max</sub>&nbsp;respectively. The concomitant use of rosuvastatin and some protease inhibitor combinations may be considered after careful consideration of rosuvastatin dose adjustments based on the expected increase in rosuvastatin exposure (see sections 4.2, 4.4 and 4.5 Table 1).</p><p><strong>Gemfibrozil and other lipid-lowering products:</strong> Concomitant use of rosuvastatin and gemfibrozil resulted in a 2-fold increase in rosuvastatin C<sub>max</sub>&nbsp;and AUC (see section 4.4).</p><p>Based on data from specific interaction studies no pharmacokinetic relevant interaction with fenofibrate is expected, however a pharmacodynamic interaction may occur. Gemfibrozil, fenofibrate, other fibrates and lipid lowering doses (&gt; or equal to 1 g/day) of niacin (nicotinic acid) increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone. The 40 mg dose is contraindicated with concomitant use of a fibrate (see sections 4.3 and 4.4). These patients should also start with the 5 mg dose.</p><p><strong>Ezetimibe:</strong>&nbsp;Concomitant use of 10 mg rosuvastatin and 10 mg ezetimibe resulted in a 1.2-fold increase in AUC of rosuvastatin in hypercholesterolaemic subjects (Table 1). A pharmacodynamic interaction, in terms of adverse effects, between rosuvastatin and ezetimibe cannot be ruled out (see section 4.4).</p><p><strong>Antacid:</strong> The simultaneous dosing of rosuvastatin with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after rosuvastatin. The clinical relevance of this interaction has not been studied.</p><p><strong>Erythromycin:</strong>&nbsp;Concomitant use of rosuvastatin and erythromycin resulted in a 20% decrease in AUC and a 30% decrease in C<sub>max</sub>&nbsp;of rosuvastatin. This interaction may be caused by the increase in gut motility caused by erythromycin.</p><p><strong>Ticagrelor:</strong> Ticagrelor might affect renal excretion of rosuvastatin, increasing the risk for rosuvastatin accumulation. Although the exact mechanism is not known, in some cases, concomitant use of ticagrelor and rosuvastatin led to renal function decrease, increased CPK level and rhabdomyolysis.</p><p><strong>Cytochrome P450 enzymes:</strong>&nbsp;Results from&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;studies show that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a poor substrate for these isoenzymes. Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected. No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and CYP3A4).</p><p><strong>Interactions requiring rosuvastatin dose adjustments (see also Table 1):</strong>&nbsp;When it is necessary to co-administer rosuvastatin with other medicinal products known to increase exposure to rosuvastatin, doses of rosuvastatin should be adjusted. Start with a 5 mg once daily dose of rosuvastatin if the expected increase in exposure (AUC) is approximately 2-fold or higher. The maximum daily dose of rosuvastatin should be adjusted so that the expected rosuvastatin exposure would not likely exceed that of a 40 mg daily dose of rosuvastatin taken without interacting medicinal products, for example a 20 mg dose of rosuvastatin with gemfibrozil (1.9-fold increase), and a 10 mg dose of rosuvastatin with combination ritonavir/atazanavir (3.1-fold increase).</p><p>If medicinal product is observed to increase rosuvastatin AUC less than 2-fold, the starting dose need not be decreased but caution should be taken if increasing the rosuvastatin dose above 20 mg.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 1 Effect of co-administered medicinal products on rosuvastatin exposure (AUC; in order of decreasing magnitude) from published clinical trials</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>2-fold or greater than 2-fold increase in AUC of rosuvastatin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Rosuvastatin dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Change in rosuvastatin AUC*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir/velpatasvir/voxilaprevir (400 mg-100 mg-100 mg) + Voxilaprevir (100 mg) once daily for 15 days</p></td><td style="vertical-align:top"><p>10mg single dose</p></td><td style="vertical-align:top"><p>7.4 -fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin 75 mg BID to 200 mg BID, 6 months</p></td><td style="vertical-align:top"><p>10 mg OD, 10 days</p></td><td style="vertical-align:top"><p>7.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Darolutamide 600 mg BID, 5 days</p></td><td style="vertical-align:top"><p>5mg, single dose</p></td><td style="vertical-align:top"><p>5.2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Regorafenib 160 mg, OD, 14 days</p></td><td style="vertical-align:top"><p>5 mg, single dose</p></td><td style="vertical-align:top"><p>3.8-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir 300 mg/ritonavir 100 mg OD, 8 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>3.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Velpatasvir 100 mg OD</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.7-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ombitasvir 25 mg/paritaprevir 150 mg/ Ritonavir 100 mg OD/ dasabuvir 400 mg BID, 14 days</p></td><td style="vertical-align:top"><p>5 mg, single dose</p></td><td style="vertical-align:top"><p>2.6-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Teriflunomide</p></td><td style="vertical-align:top"><p>Not available</p></td><td style="vertical-align:top"><p>2.5-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Grazoprevir 200 mg/elbasvir 50 mg OD, 11 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.3-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Glecaprevir 400 mg/pibrentasvir 120 mg OD, 7 days</p></td><td style="vertical-align:top"><p>5 mg OD, 7 days</p></td><td style="vertical-align:top"><p>2.2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir 400 mg/ritonavir 100 mg BID, 17 days</p></td><td style="vertical-align:top"><p>20 mg OD, 7 days</p></td><td style="vertical-align:top"><p>2.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Capmatinib 400mg BID</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Clopidogrel 300 mg loading, followed by 75 mg at 24 hours</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Fostamatinib 100 mg twice daily</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>2.0-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Febuxostat 120 mg OD</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.9-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Gemfibrozil 600 mg BID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>1.9-fold &uarr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Less than 2-fold increase in AUC of rosuvastatin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Rosuvastatin dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Change in rosuvastatin AUC<sup>*</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Eltrombopag 75 mg OD, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.6-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir 600 mg/ritonavir 100 mg BID, 7 days</p></td><td style="vertical-align:top"><p>10 mg OD, 7 days</p></td><td style="vertical-align:top"><p>1.5-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir 500 mg/ritonavir 200 mg BID, 11 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Dronedarone 400 mg BID</p></td><td style="vertical-align:top"><p>Not available</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole 200 mg OD, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>**1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ezetimibe 10 mg OD, 14 days</p></td><td style="vertical-align:top"><p>10 mg, OD, 14 days</p></td><td style="vertical-align:top"><p>**1.2-fold &uarr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Decrease in AUC of rosuvastatin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Rosuvastatin dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Change in rosuvastatin AUC<sup>*</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin 500 mg QID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>20% &darr;</p></td></tr><tr><td style="vertical-align:top"><p>Baicalin 50 mg TID, 14 days</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>47% &darr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>Data given as x-fold change represent a simple ratio between co-administration and rosuvastatin alone. Data given as % change represent % difference relative to rosuvastatin alone.</p><p>Increase is indicated as &ldquo;&uarr;<u>&rdquo;,</u>&nbsp;decrease as &ldquo;&darr;&rdquo;.</p><p><sup>**</sup>Several interaction studies have been performed at different rosuvastatin dosages, the table shows the most significant ratio</p><p>AUC = area under curve; OD = once daily; BID = twice daily; TID = three times daily; QID = four times daily</p></td></tr></tbody></table><p>The following medical product/combinations did not have a clinically significant effect on the AUC ratio of rosuvastatin at coadministration:</p><p>Aleglitazar 0.3 mg 7 days dosing; Fenofibrate 67 mg 7 days TID dosing; Fluconazole 200mg 11 days OD dosing; Fosamprenavir 700 mg/ritonavir 100 mg 8 days BID dosing; Ketoconazole 200 mg 7 days BID dosing; Rifampin 450 mg 7 days OD dosing; Silymarin 140 mg 5 days TID dosing.</p><p><strong><em>Effect of rosuvastatin on co-administered medicinal products</em></strong></p><p><strong>Vitamin K antagonists:&nbsp;</strong>As with other HMG-CoA reductase inhibitors, the initiation of treatment or dosage up-titration of rosuvastatin in patients treated concomitantly with vitamin K antagonists (e.g. warfarin or another coumarin anticoagulant) may result in an increase in International Normalised Ratio (INR). Discontinuation or down-titration of rosuvastatin may result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable.</p><p><strong>Oral contraceptive/hormone replacement therapy (HRT):&nbsp;</strong>Concomitant use of rosuvastatin and an oral contraceptive resulted in an increase in ethinyl estradiol and norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be considered when selecting oral contraceptive doses. There are no pharmacokinetic data available in subjects taking concomitant rosuvastatin and HRT, therefore, a similar effect cannot be excluded. However, the combination has been extensively used in women in clinical trials and was well tolerated.</p><p><strong>Other medicinal products:</strong></p><p><em>Digoxin:</em>&nbsp;Based on data from specific interaction studies no clinically relevant interaction with digoxin is expected.</p><p><em>Fusidic Acid:</em>&nbsp;Interaction studies with rosuvastatin and fusidic acid have not been conducted. The risk of myopathy, including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.</p><p>If treatment with systemic fusidic acid is necessary, rosuvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment.&nbsp;<strong>Also see section 4.4.</strong></p><p><strong>Paediatric population:&nbsp;</strong>Interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Resova is contraindicated in pregnancy and lactation.</p><p>Women of child bearing potential should use appropriate contraceptive measures.</p><p>Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. Animal studies provide limited evidence of reproductive toxicity (see section 5.3). If a patient becomes pregnant during use of this product, treatment should be discontinued immediately.</p><p>Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in humans (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies to determine the effect of rosuvastatin on the ability to drive and use machines have not been conducted. However, based on its pharmacodynamic properties, rosuvastatin is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions seen with rosuvastatin are generally mild and transient. In controlled clinical trials, less than 4% of rosuvastatin-treated patients were withdrawn due to adverse reactions.</p><p><u>Tabulated list of adverse reactions</u></p><p>Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for rosuvastatin. Adverse reactions listed below are classified according to frequency and system organ class (SOC).</p><p>The frequencies of adverse reactions are ranked according to the following convention: Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p><strong>Table 2. Adverse reactions based on data from clinical studies and post-marketing experience</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity reactions including angioedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Diabetes mellitus<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Polyneuropathy</p><p>Memory loss</p></td><td style="vertical-align:top"><p>Peripheral neuropathy</p><p>Sleep disturbances (including insomnia and nightmares)</p><p>Myasthenia gravis</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ocular myasthenia</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cough</p><p>Dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>Gastro-intestinal disorders</p></td><td style="vertical-align:top"><p>Constipation</p><p>Nausea</p><p>Abdominal pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Increased hepatic transaminases</p></td><td style="vertical-align:top"><p>Jaundice</p><p>Hepatitis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pruritus</p><p>Rash</p><p>Urticaria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Stevens-Johnson syndrome</p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p>Musculo-skeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Myopathy (including myositis)</p><p>Rhabdomyolysis</p><p>Lupus-like syndrome</p><p>Muscle rupture</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Tendon disorders, sometimes complicated by rupture</p><p>Immune-mediated necrotising myopathy</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Oedema</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>1&nbsp;</sup>Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge; 5.6 mmol/L, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, history of hypertension).</p></td></tr></tbody></table><p>As with other HMG-CoA reductase inhibitors, the incidence of adverse drug reactions tends to be dose dependent.</p><p><strong>Renal effects:&nbsp;</strong>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with rosuvastatin. Shifts in urine protein from none or trace to ++ or more were seen in &lt;1% of patients at some time during treatment with 10 and 20 mg, and in approximately 3% of patients treated with 40 mg. A minor increase in shift from none or trace to + was observed with the 20 mg dose. In most cases, proteinuria decreases or disappears spontaneously on continued therapy. Review of data from clinical trials and post-marketing experience to date has not identified a causal association between proteinuria and acute or progressive renal disease.</p><p>Haematuria has been observed in patients treated with rosuvastatin and clinical trial data show that the occurrence is low.</p><p><strong>Skeletal muscle effects:&nbsp;</strong>Effects on skeletal muscle e.g. myalgia, myopathy (including myositis) and, rarely, rhabdomyolysis with and without acute renal failure have been reported in rosuvastatin-treated patients with all doses and in particular with doses &gt; 20 mg.</p><p>A dose-related increase in CK levels has been observed in patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient. If CK levels are elevated (&gt;5xULN), treatment should be discontinued (see section 4.4).</p><p><strong>Liver effects:&nbsp;</strong>As with other HMG-CoA reductase inhibitors, a dose-related increase in transaminases has been observed in a small number of patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient.</p><p>The following adverse events have been reported with some statins:</p><p>Sexual dysfunction.</p><p>Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4).</p><p>The reporting rates for rhabdomyolysis, serious renal events and serious hepatic events (consisting mainly of increased hepatic transaminases) is higher at the 40 mg dose.</p><p><strong>Paediatric population:</strong>&nbsp;Creatine kinase elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently in a 52-week clinical trial of children and adolescents compared to adults (see section 4.4). In other respects, the safety profile of rosuvastatin was similar in children and adolescents compared to adults.</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa</p><p>Website: https: //ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Liver function and CK levels should be monitored. Haemodialysis is unlikely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:&nbsp;</strong>HMG-CoA reductase inhibitors.</p><p><strong>ATC code:&nbsp;</strong>C10A A07</p><p><strong>Mechanism of action</strong></p><p>Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol lowering.</p><p>Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.</p><p><strong>Pharmacodynamic effects</strong></p><p>Rosuvastatin reduces elevated LDL-cholesterol, total cholesterol and triglycerides and increases HDL-cholesterol. It also lowers ApoB, non-HDL-C, VLDL-C, VLDL-TG and increases ApoA-I (see Table 3). Rosuvastatin also lowers the LDL-C/HDL-C, total C/HDL-C and non-HDL-C/HDL-C and the ApoB/ApoA-I ratios.</p><p><strong>Table 3 Dose response in patients with primary hypercholesterolaemia (type IIa and IIb) (adjusted mean percent change from baseline)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>LDL-C</strong></p></td><td style="vertical-align:top"><p><strong>Total-C</strong></p></td><td style="vertical-align:top"><p><strong>HDL-C</strong></p></td><td style="vertical-align:top"><p><strong>TG</strong></p></td><td style="vertical-align:top"><p><strong>nonHDL-C</strong></p></td><td style="vertical-align:top"><p><strong>ApoB</strong></p></td><td style="vertical-align:top"><p><strong>ApoA-I</strong></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-5</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-45</p></td><td style="vertical-align:top"><p>-33</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-35</p></td><td style="vertical-align:top"><p>-44</p></td><td style="vertical-align:top"><p>-38</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-52</p></td><td style="vertical-align:top"><p>-36</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>-10</p></td><td style="vertical-align:top"><p>-48</p></td><td style="vertical-align:top"><p>-42</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-55</p></td><td style="vertical-align:top"><p>-40</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>-23</p></td><td style="vertical-align:top"><p>-51</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>-63</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>-28</p></td><td style="vertical-align:top"><p>-60</p></td><td style="vertical-align:top"><p>-54</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>A therapeutic effect is obtained within 1 week following treatment initiation and 90% of maximum response is achieved in 2 weeks. The maximum response is usually achieved by 4 weeks and is maintained after that.</p><p><strong>Clinical efficacy and safety</strong></p><p>Rosuvastatin is effective in adults with hypercholesterolaemia, with and without hypertriglyceridaemia, regardless of race, sex or age and in special populations such as diabetics or patients with familial hypercholesterolaemia.</p><p>From pooled phase III data, rosuvastatin has been shown to be effective at treating the majority of patients with type IIa and IIb hypercholesterolaemia (mean baseline LDL-C about 4.8 mmol/L) to recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about 80% of patients treated with 10 mg reached the EAS targets for LDL-C levels (&lt;3 mmol/L).</p><p>In a large study, 435 patients with heterozygous familial hypercholesterolaemia were given rosuvastatin from 20 mg to 80 mg in a force-titration design. All doses showed a beneficial effect on lipid parameters and treatment to target goals. Following titration to a daily dose of 40 mg (12 weeks of treatment), LDL-C was reduced by 53%. Thirty-three percent (33%) of patients reached EAS guidelines for LDL-C levels (&lt;3 mmol/L).</p><p>In a force-titration, open label trial, 42 patients (including 8 paediatric patients) with homozygous familial hypercholesterolaemia were evaluated for their response to rosuvastatin 20 &ndash; 40 mg. In the overall population, the mean LDL-C reduction was 22%.</p><p>In clinical studies with a limited number of patients, rosuvastatin has been shown to have additive efficacy in lowering triglycerides when used in combination with fenofibrate and in increasing HDL-C levels when used in combination with niacin (see section 4.4).</p><p>In a multi-centre, double-blind, placebo-controlled clinical study (METEOR), 984 patients between 45 and 70 years of age and at low risk for coronary heart disease (defined as Framingham risk &lt;10% over 10 years), with a mean LDL-C of 4.0 mmol/L (154.5 mg/dL), but with subclinical atherosclerosis (detected by Carotid Intima Media Thickness) were randomised to 40 mg rosuvastatin once daily or placebo for 2 years. Rosuvastatin significantly slowed the rate of progression of the maximum CIMT for the 12 carotid artery sites compared to placebo by -0.0145 mm/year [95% confidence interval -0.0196, -0.0093; p&lt;0.0001]. The change from baseline was -0.0014 mm/year (-0.12%/year (non-significant)) for rosuvastatin compared to a progression of +0.0131 mm/year (1.12%/year (p&lt;0.0001)) for placebo. No direct correlation between CIMT decrease and reduction of the risk of cardiovascular events has yet been demonstrated. The population studied in METEOR is low risk for coronary heart disease and does not represent the target population of rosuvastatin 40 mg. The 40 mg dose should only be prescribed in patients with severe hypercholesterolaemia at high cardiovascular risk (see section 4.2).</p><p>In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect of rosuvastatin on the occurrence of major atherosclerotic cardiovascular disease events was assessed in 17,802 men (&ge;50 years) and women (&ge;60 years).</p><p>Study participants were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once daily (n=8901) and were followed for a mean duration of 2 years.</p><p>LDL-cholesterol concentration was reduced by 45% (p&lt;0.001) in the rosuvastatin group compared to the placebo group.</p><p>In a post-hoc analysis of a high-risk subgroup of subjects with a baseline Framingham risk score &gt;20% (1558 subjects) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.028) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate per 1000 patient-years was 8.8. Total mortality was unchanged in this high-risk group (p=0.193). In a post-hoc analysis of a high-risk subgroup of subjects (9302 subjects total) with a baseline SCORE risk &ge;5% (extrapolated to include subjects above 65 yrs) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.0003) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate was 5.1 per 1000 patient-years. Total mortality was unchanged in this high-risk group (p=0.076).</p><p>In the JUPITER trial, there were 6.6% of rosuvastatin and 6.2% of placebo subjects who discontinued use of study medication due to an adverse event. The most common adverse events that led to treatment discontinuation were: myalgia (0.3% rosuvastatin, 0.2% placebo), abdominal pain (0.03% rosuvastatin, 0.02% placebo) and rash (0.02% rosuvastatin, 0.03% placebo). The most common adverse events at a rate greater than or equal to placebo were urinary tract infection (8.7% rosuvastatin, 8.6% placebo), nasopharyngitis (7.6% rosuvastatin, 7.2% placebo), back pain (7.6% rosuvastatin, 6.9% placebo) and myalgia (7.6% rosuvastatin, 6.6% placebo).</p><p><strong>Paediatric population</strong></p><p>In a double-blind, randomised, multi-centre, placebo-controlled, 12-week study (n=176, 97 male and 79 female) followed by a 40-week (n=173, 96 male and 77 female), open-label, rosuvastatin dose-titration phase, patients 10 to 17 years of age (Tanner stage II-V, females at least 1-year post-menarche) with heterozygous familial hypercholesterolaemia received rosuvastatin 5, 10 or 20 mg or placebo daily for 12 weeks and then all received rosuvastatin daily for 40 weeks. At study entry, approximately 30% of the patients were 10 to 13 years and approximately 17%, 18%, 40%, and 25% were Tanner stage II, III, IV, and V, respectively.</p><p>LDL-C was reduced 38.3%, 44.6%, and 50.0% by rosuvastatin 5, 10 and 20 mg, respectively, compared to 0.7% for placebo.</p><p>At the end of the 40-week, open-label, titration to goal, dosing up to a maximum of 20 mg once daily, 70 of 173 patients (40.5%) had achieved the LDL-C goal of less than 2.8 mmol/L.</p><p>After 52 weeks of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see section 4.4). This trial (n=176) was not suited for comparison of rare adverse drug events.</p><p>Rosuvastatin was also studied in a 2-year open-label, titration-to-goal study in 198 children with heterozygous familial hypercholesterolaemia aged 6 to 17 years (88 male and 110 female, Tanner stage &lt;II-V). The starting dose for all patients was 5 mg rosuvastatin once daily. Patients aged 6 to 9 years (n=64) could titrate to a maximum dose of 10 mg once daily and patients aged 10 to 17 years (n=134) to a maximum dose of 20 mg once daily.</p><p>After 24 months of treatment with rosuvastatin, the LS mean percent reduction from the baseline value in LDL-C was -43% (Baseline: 236 mg/dL, Month 24: 133 mg/dL). For each age group, the LS mean percent reductions from baseline values in LDL-C were -43% (Baseline: 234 mg/dL, Month 24: 124 mg/dL), -45% (Baseline: 234 mg/dL, Month 24: 124 mg/dL) and -35% (Baseline: 241 mg/dL, Month 24: 153 mg/dL) in the 6 to &lt;10, 10 to &lt;14, and 14 to &lt;18 age groups, respectively.</p><p>Rosuvastatin 5 mg, 10 mg, and 20 mg also achieved statistically significant mean changes from baseline for the following secondary lipid and lipoprotein variables: HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, TG/HDL-C, non-HDL C/HDL-C, ApoB, ApoB/ApoA-1. These changes were each in the direction of improved lipid responses and were sustained over 2 years.</p><p>No effect on growth, weight, BMI or sexual maturation was detected after 24 months of treatment (see section 4.4).</p><p>Rosuvastatin was studied in a randomised, double-blind, placebo-controlled, multi-centre, cross-over study with 20 mg once daily versus placebo in 14 children and adolescents (aged from 6 to 17 years) with homozygous familial hypercholesterolaemia. The study included an active 4-week dietary lead-in phase during which patients were treated with rosuvastatin 10 mg, a cross-over phase that consisted of a 6-week treatment period with rosuvastatin 20 mg preceded or followed by a 6-week placebo treatment period, and a 12-week maintenance phase during which all patients were treated with rosuvastatin 20 mg. Patients who entered the study on ezetimibe or apheresis therapy continued the treatment throughout the entire study.</p><p>A statistically significant (p=0.005) reduction in LDL-C (22.3%, 85.4 mg/dL or 2.2 mmol/L) was observed following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. Statistically significant reductions in Total-C (20.1%, p=0.003), non-HDL-C (22.9%, p=0.003) and ApoB (17.1%, p=0.024) were observed. Reductions were also seen in TG, LDL-C/HDL-C, Total-C/HDL-C, non-HDL-C/HDL-C and ApoB/ApoA-1 following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. The reduction in LDL-C after 6 weeks of treatment with rosuvastatin 20 mg following 6 weeks of treatment with placebo was maintained over 12 weeks of continuous therapy. One patient had a further reduction in LDL-C (8.0%), Total-C (6.7%) and non-HDL-C (7.4%) following 6 weeks of treatment with 40 mg after up-titration.</p><p>During an extended open-label treatment in 9 of these patients with 20 mg rosuvastatin for up to 90 weeks, the LDL-C reduction was maintained in the range of -12.1% to -21.3%.</p><p>In the 7 evaluable children and adolescent patients (aged from 8 to 17 years) from the force-titration open label study with homozygous familial hypercholesterolaemia (see above), the percent reduction in LDL-C (21.0%), Total-C (19.2%) and non-HDL-C (21.0%) from baseline following 6 weeks of treatment with rosuvastatin 20 mg was consistent with that observed in the aforementioned study in children and adolescents with homozygous familial hypercholesterolaemia.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with rosuvastatin in all subsets of the paediatric population in the treatment of homozygous familial hypercholesterolaemia, primary combined (mixed) dyslipidaemia and in the prevention of cardiovascular events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption:</strong>&nbsp;Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours after oral administration. The absolute bioavailability is approximately 20%.</p><p><strong>Distribution</strong>: Rosuvastatin is taken up extensively by the liver which is the primary site of cholesterol synthesis and LDL-C clearance. The volume of distribution of rosuvastatin is approximately 134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.</p><p><strong>Metabolism:</strong>&nbsp;Rosuvastatin undergoes limited metabolism (approximately 10%).&nbsp;<em>In vitro</em>&nbsp;metabolism studies using human hepatocytes indicate that rosuvastatin is a poor substrate for cytochrome P450-based metabolism. CYP2C9 was the principal isoenzyme involved, with 2C19, 3A4 and 2D6 involved to a lesser extent. The main metabolites identified are the N-desmethyl and lactone metabolites. The N-desmethyl metabolite is approximately 50% less active than rosuvastatin whereas the lactone form is considered clinically inactive. Rosuvastatin accounts for greater than 90% of the circulating HMG-CoA reductase inhibitor activity.</p><p><strong>Excretion:</strong>&nbsp;Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces (consisting of absorbed and non-absorbed active substance) and the remaining part is excreted in urine. Approximately 5% is excreted unchanged in urine. The plasma elimination half-life is approximately 19 hours. The elimination half-life does not increase at higher doses. The geometric mean plasma clearance is approximately 50 litres/hour (coefficient of variation 21.7%). As with other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin involves the membrane transporter OATP-C. This transporter is important in the hepatic elimination of rosuvastatin.</p><p><strong>Linearity:</strong>&nbsp;Systemic exposure of rosuvastatin increases in proportion to dose. There are no changes in pharmacokinetic parameters following multiple daily doses.</p><p><strong><em>Special populations:</em></strong></p><p><strong>Age and sex:&nbsp;</strong>There was no clinically relevant effect of age or sex on the pharmacokinetics of rosuvastatin in adults. The exposure in children and adolescents with heterozygous familial hypercholesterolemia appears to be similar to or lower than that in adult patients with dyslipidaemia (see &ldquo;Paediatric population&rdquo; below).</p><p><strong>Race:</strong>&nbsp;Pharmacokinetic studies show an approximate 2-fold elevation in median AUC and C<sub>max</sub>&nbsp;in Asian subjects (Japanese, Chinese, Filipino, Vietnamese and Koreans) compared with Caucasians; Asian-Indians show an approximate 1.3-fold elevation in median AUC and C<sub>max</sub>. A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics between Caucasian and Black groups.</p><p><strong>Renal insufficiency:</strong>&nbsp;In a study in subjects with varying degrees of renal impairment, mild to moderate renal disease had no influence on plasma concentration of rosuvastatin or the N-desmethyl metabolite. Subjects with severe impairment (CrCl &lt;30 ml/min) had a 3-fold increase in plasma concentration and a 9-fold increase in the N-desmethyl metabolite concentration compared to healthy volunteers. Steady-state plasma concentrations of rosuvastatin in subjects undergoing haemodialysis were approximately 50% greater compared to healthy volunteers.</p><p><strong>Hepatic insufficiency:</strong>&nbsp;In a study with subjects with varying degrees of hepatic impairment, there was no evidence of increased exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, two subjects with Child-Pugh scores of 8 and 9 showed an increase in systemic exposure of at least 2-fold compared to subjects with lower Child-Pugh scores. There is no experience in subjects with Child-Pugh scores above 9.</p><p><strong>Genetic polymorphisms:</strong>&nbsp;Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and BCRP transporter proteins. In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure. Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with a higher rosuvastatin exposure (AUC) compared to the SLCO1B1 c.521TT or ABCG2 c.421CC genotypes. This specific genotyping is not established in clinical practice, but for patients who are known to have these types of polymorphisms, a lower daily dose of rosuvastatin is recommended.</p><p><strong>Paediatric population:</strong>&nbsp;Two pharmacokinetic studies with rosuvastatin (given as tablets) in paediatric patients with heterozygous familial hypercholesterolaemia 10 to 17 or 6 to 17 years of age (total of 214 patients) demonstrated that exposure in paediatric patients appears comparable to or lower than that in adult patients. Rosuvastatin exposure was predictable with respect to dose and time over a 2-year period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenicity potential. Specific tests for effects on hERG have not been evaluated. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels were as follows: In repeated-dose toxicity studies histopathologic liver changes likely due to the pharmacologic action of rosuvastatin were observed in mouse, rat, and to a lesser extent with effects in the gall bladder in dogs, but not in monkeys. In addition, testicular toxicity was observed in monkeys and dogs at higher dosages. Reproductive toxicity was evident in rats, with reduced litter sizes, litter weight and pup survival observed at maternally toxic doses, where systemic exposures were several times above the therapeutic exposure level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet core: </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Lactose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Calcium phosphate dihydrate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Crospovidone</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline cellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate</p><p><em>Tablet coat:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Opadry pink</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/aluminum blisters.</p><p>Pack size: 30 Film-coated Tablets. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11 January 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>